- Home
- EMBC
EMBC
Embecta Corp.
as 07-26-2024 4:00pm EST
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
| Founded: | 1924 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 759.5M | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 445.9K |
| Analyst Decision: | Sell | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.21 | EPS Growth: | -27.54 |
| 52 Week Low/High: | $9.93 - $23.75 | Next Earning Date: | 08-09-2024 |
| Revenue: | $1,132,500,000 | Revenue Growth: | 1.25% |
| Revenue Growth (this year): | 1.53% | Revenue Growth (next year): | 0.35% |
Latest Embecta Corp. News
EMBC Breaking Stock News: Dive into EMBC Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Strength Seen in Embecta Corp. (EMBC): Can Its 6.9% Jump Turn into More Strength?
Argus Research
3 days ago
EMBC: Raising target price to $17.00
MedTech Dive
5 days ago
Diabetes device firm Embecta considers sale: Financial Times
GlobeNewswire
8 days ago
embecta to Report Fiscal Third Quarter 2024 Financial Results
Argus Research
10 days ago
EMBC: Raising target price to $14.00
Argus Research
17 days ago
EMBC: What does Argus have to say about EMBC?
MedTech Dive
a month ago
Embecta touts its insulin patch pump at ADA
GlobeNewswire
a month ago
embecta-sponsored Abstracts Presented at American Diabetes Association’s 84th Scientific Sessions Highlight Unmet Need for Patch Pumps with 300u Insulin Reservoir
Compare EMBC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EMBC Embecta Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.